Patents Assigned to Mesoblast International Sarl
-
Publication number: 20170340674Abstract: The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.Type: ApplicationFiled: December 22, 2015Publication date: November 30, 2017Applicant: Mesoblast International SàrlInventors: Silviu Itescu, Lee Golden
-
Patent number: 9828586Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: GrantFiled: December 23, 2013Date of Patent: November 28, 2017Assignee: MESOBLAST INTERNATIONAL SÁRLInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Publication number: 20170333482Abstract: The present disclosure relates to methods for treating or preventing heart failure in subjects with elevated left ventricular end systolic volume (LVESV). In particular, the present disclosure related to methods for treating or preventing heart failure in subjects with a LVESV of greater than 70 ml (>70 ml).Type: ApplicationFiled: December 22, 2015Publication date: November 23, 2017Applicant: Mesoblast International SàrlInventors: Silviu Itescu, Lee Golden
-
Patent number: 9814580Abstract: A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.Type: GrantFiled: April 16, 2015Date of Patent: November 14, 2017Assignee: MESOBLAST INTERNATIONAL SARLInventors: Francis P. Barry, J. Mary Murphy, Robert Deans, David J. Fink, Annemarie Moseley
-
Patent number: 9694035Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.Type: GrantFiled: July 17, 2014Date of Patent: July 4, 2017Assignee: MESOBLAST INTERNATIONAL SARLInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Publication number: 20170107495Abstract: The disclosure provides stem cells which express high levels of Angeopoetin-1 (Ang1) and methods for their production. Such stem cells may be used in a range of therapeutic application.Type: ApplicationFiled: April 7, 2015Publication date: April 20, 2017Applicant: Mesoblast International SarlInventors: Silviu Itescu, Paul Simmons
-
Publication number: 20170106023Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.Type: ApplicationFiled: June 1, 2015Publication date: April 20, 2017Applicant: Mesoblast International SarlInventors: Silviu Itescu, Paul Simmons
-
Patent number: 9308277Abstract: The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity.Type: GrantFiled: February 17, 2011Date of Patent: April 12, 2016Assignee: Mesoblast International SàrlInventors: Vincent Frans Maria Segers, Anthony Sandrasagra, Yan Qiu
-
Patent number: 9050178Abstract: A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.Type: GrantFiled: January 16, 2013Date of Patent: June 9, 2015Assignee: MESOBLAST INTERNATIONAL SÀRLInventors: Francis P. Barry, J. Mary Murphy, Robert Deans, David J. Fink, Annemarie Moseley
-
Patent number: 8852571Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: February 9, 2012Date of Patent: October 7, 2014Assignee: Mesoblast International SarlInventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
-
Patent number: 8852570Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: February 9, 2012Date of Patent: October 7, 2014Assignee: Mesoblast International SarlInventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
-
Patent number: 8852575Abstract: Disclosed are compositions and methods for method of treating a subject having reduced cardiac function or cardiac disease by administering adult bone marrow-derived stem cells to an individual. In some embodiments, the subject is a myocardial infarction patient or congestive heart failure patient. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: July 2, 2012Date of Patent: October 7, 2014Assignee: Mesoblast International SarlInventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
-
Patent number: 8852574Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: February 9, 2012Date of Patent: October 7, 2014Assignee: Mesoblast International SarlInventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
-
Patent number: 8852572Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: February 9, 2012Date of Patent: October 7, 2014Assignee: Mesoblast International SarlInventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
-
Patent number: 8852573Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: February 9, 2012Date of Patent: October 7, 2014Assignee: Mesoblast International SarlInventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
-
Publication number: 20140161776Abstract: Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.Type: ApplicationFiled: December 23, 2013Publication date: June 12, 2014Applicant: MESOBLAST INTERNATIONAL SARLInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Publication number: 20140154276Abstract: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.Type: ApplicationFiled: November 22, 2013Publication date: June 5, 2014Applicant: MESOBLAST INTERNATIONAL SÁRLInventors: Sudeepta Aggarwal, Mark F. Pittenger, Timothy Varney
-
Publication number: 20140112893Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: Mesoblast International SarlInventors: Samson Tom, Christopher Ton, Alla Danilkovitch
-
Patent number: 8637004Abstract: One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.Type: GrantFiled: August 14, 2009Date of Patent: January 28, 2014Assignee: Mesoblast International SarlInventors: Alla Danilkovich, Robert E. Newman, Jr., Samson Tom, Christopher Ton, Zhanling Wang, Randell G. Young